2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD3
  5. CD3 Inhibitor

CD3 Inhibitor

CD3 Inhibitors (27):

Cat. No. Product Name Effect Purity
  • HY-P99033
    Mosunetuzumab
    		Inhibitor 99.05%
    Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs).
  • HY-P990925
    Linclatamig
    		Inhibitor
    HY-P990925 is an CD3E-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
  • HY-P990920
    Gocatamig
    		Inhibitor
    HY-P990920 is an CD3E/ALB/DLL3-targeting (scFv-heavy-lamdba)-VH-VH' type chimeric humanized antibody.
  • HY-P990717
    Brenetafusp
    		Inhibitor
    Brenetafusp is an anti-CD3E/PRAME monoclonal antibody.
  • HY-P99592
    Solitomab
    		Inhibitor 98.22%
    Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer.
  • HY-P99762
    Obrindatamab
    		Inhibitor 99.58%
    Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer.
  • HY-P99124
    Anti-Mouse CD3 Antibody (17A2)
    		Inhibitor
    Anti-Mouse CD3 Antibody is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat.
  • HY-P9989
    Linvoseltamab
    		Inhibitor 99.71%
    Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models.
  • HY-P99814
    Pavurutamab
    		Inhibitor
    Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM).
  • HY-P99802
    Pasotuxizumab
    		Inhibitor 98.02%
    Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
  • HY-P99757
    Nivatrotamab
    		Inhibitor 99.40%
    Nivatrotamab (Hu3F8-BsAb) is a humanized anti-GD2/CD3 bispecific antibody. Nivatrotamab is a CD3- and GD2-specific bsAb-based T-cell engager. Nivatrotamab can be used in research of neuroblastoma.
  • HY-P99776
    Plamotamab
    		Inhibitor 99.12%
    Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo.
  • HY-P99146
    Anti-Mouse TCR gamma/delta Antibody (UC7-13D5)
    		Inhibitor
    Anti-Mouse TCR gamma/delta Antibody is an anti-mouse TCR gamma/delta IgG antibody inhibitor derived from host Armenian Hamster.
  • HY-P990095
    Vonsetamig
    		Inhibitor
    Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E bispecific antibody. Vonsetamig is an antineoplastic.
  • HY-P990903
    Avitotamig
    		Inhibitor
    HY-P990903 is an CD3E/CD33-targeting [H-γ1 _ L-κ-scFv heavy -κ]-dimer type bispecific antibody.
  • HY-P990955
    Ebribafusp alfa
    		Inhibitor
    HY-P990955 is an CD3E-targeting IgG4κ type chimeric antibody, the recommed isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
  • HY-P990932
    Obrixtamig
    		Inhibitor
    HY-P990932 is an CD3E/HEK-targeting L-κ-G1-h-CH2-CH3_L-λ-G1-h-CH2-CH3 type human antibodychimeric antibody.
  • HY-P991015
    Pasritamig
    		Inhibitor
    HY-P991015 is an KLK2/CD3E-targeting (H-γ1_L-κ)_scFvkh-G1(h-CH2-CH3) type bispecific antibody.
  • HY-P990928
    Mipletamig
    		Inhibitor
    HY-P990928 is an CD3E-targeting [(scFv -κ-heavy) G1-h-CH2-CH3 (scFv-heavy -κ)]2 type chimeric human and humanized antibody.
  • HY-P990953
    Zubotamig
    		Inhibitor
    HY-P990953 is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody.